23 June 2016
EMA/427430/2016
Press Office

Start of community reviews

CHMP meeting of 20-23 June 2016

Table 1. Start of reviews for non-centrally authorised medicines

Name	INN	Type of procedure	Scope
Pharmaceutics International		Article 31 of Directive 2001/83/EC	Procedure triggered by the European Commission following the issue of a GMP non-compliance statement for the manufacturing site Pharmaceutics International Inc. located in Maryland, USA. The EMA's Committee for Medicinal Products for Human Use (CHMP) will now review the impact of the inspection findings that led to the withdrawal of the GMP certificate on products that include the above mentioned manufacturing site in their marketing authorisation.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged.